Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.19 USD

166.19
636,152

+2.02 (1.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Insulet (PODD) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

by Zacks Equity Research

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility

by Zacks Equity Research

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).

Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Insulet (PODD) Gains From Product Innovation, Global Expansion

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes

by Zacks Equity Research

Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

by Zacks Equity Research

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Here's Why Insulet (PODD) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

by Zacks Equity Research

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

by Zacks Equity Research

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.